pharma news today glp-1 obesity drugs today Giants Bet on Next-Generation Treatments to Sustain Growth The GLP-1 Access Gap: Mapping
Description
The program is medically facilitated, ACLM-certified, and grounded in the science of whole-food plant-based nutrition
PMC 5114298
Marre M, Shaw J, Brndle M, et al
The REWIND trial, targeting cardiovascular events in T2DM participants without previous cardiovascular history, found that dulaglutide reduced cardiovascular outcomes, and was well tolerated [61]
The manufacturers of these drugs have priced them at more than $1,000 per month, and limited competition in the space is putting them out of reach for many patients and creating financial burden on healthcare systems
